Dyne Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Highlights
March 04, 2021 07:35 ET
|
Dyne Therapeutics, Inc.
- Preclinical Data Further Validate FORCE™ Platform; Driving Toward IND Submissions for DM1, DMD and FSHD Programs Between Q4’21 and Q4’22 - - Recent Appointments to Experienced Leadership Team...
Dyne Therapeutics Appoints Wildon Farwell, M.D., MPH, as Chief Medical Officer
March 04, 2021 07:25 ET
|
Dyne Therapeutics, Inc.
Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) --...
Dyne Therapeutics Appoints Ashish Dugar, Ph.D., MBA, Senior Vice President, Global Head of Medical Affairs
February 08, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease WALTHAM, Mass., Feb. 08, 2021 (GLOBE...
Dyne Therapeutics Announces Pricing of $168 Million Public Offering
January 20, 2021 20:05 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
January 10, 2021 15:00 ET
|
Dyne Therapeutics, Inc.
- In Vivo Model Developed by Dyne Sets New Standard for Evaluating Pharmacodynamics in DM1 - - Preclinical Data Further Validate FORCE™ Platform; IND Submissions Planned for DM1, DMD and FSHD...
Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics to Present at Upcoming Investor Conferences
November 09, 2020 07:30 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...
Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights
November 05, 2020 07:35 ET
|
Dyne Therapeutics, Inc.
- Successful Financings, including $268 Million Initial Public Offering and $116 Million Series B Expected to Fund Through Proof of Concept Data in Co-lead Programs, Myotonic Dystrophy Type 1 and...
Dyne Therapeutics Announces Closing of Initial Public Offering
September 21, 2020 16:05 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with...
Dyne Therapeutics Announces Pricing of Initial Public Offering
September 16, 2020 19:00 ET
|
Dyne Therapeutics, Inc.
WALTHAM, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with...